Maria Ornella Nicoletto

Author

Also Known As

M O Nicoletto, M. Nicoletto, M. O. Nicoletto, M. Ornella Nicoletto, M.O. NICOLETTO, M.O. Nicoletto, MARIA ORNELLA NICOLETTO, Maria Clara Caudana, Maria Nicoletto, Maria O Nicoletto

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Istituto Oncologico Veneto Istituti di Ricovero e Cura a Carattere Scientifico University of Padua European Institute of Oncology Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

About

Maria Ornella Nicoletto is an author at Istituto Oncologico Veneto specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	2.6K
2	Obstetrics	12	15	2.6K
3	Health Sciences	4	4	86
4	Public Health	1	1	11
5	Biostatistics	1	1	11

Maria Ornella Nicoletto

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391
Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation Anna Pastò, Chiara Bellio, Giorgia Pilotto, Oncotarget	2014	282
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard, The Lancet Oncology Placebo-controlled Phase 3MedicineMetronomic TherapyGynecologyStandard First-line Chemotherapy	2015	207
Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer Catherine Lhommé, Florence Joly, Joan L. Walker, Journal of Clinical Oncology	2008	154
Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells Anna Pagotto, Giorgia Pilotto, Elena Laura Mazzoldi, Cell Death and Disease	2017	144
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial Michael Friedländer, Val Gebski, Emma Gibbs, The Lancet Oncology Olaparib MaintenanceHealth-related QualityMedicineCancer ManagementGynecology	2018	135
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, Molecular Cancer Therapeutics	2011	93
Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. Sandro Pignata, Domenica Lorusso, Florence Joly, Journal of Clinical Oncology First Line TreatmentMedicineRoc PatientsCancer ManagementPlatinum-based Doublets	2018	73
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer Nicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici, Gynecologic Oncology Phase Ii TrialMedicineGynecologyWeekly PaclitaxelIntermittent Schedule	2022	67

Page 1